Robert Kay Net Worth

Robert Kay biography

Robert B. Kay J.D. serves as Interim Secretary, Interim Treasurer, Director of the Company. Mr. Kay served as our Executive Chair and Chief Executive Officer from August 2008 to March 2020, as Executive Co-Chair from March 2020 through June 2020, and has served as a director of the Board since August 2008. In September 2020, Mr. Kay was appointed as our Interim Secretary and Interim Treasurer. Previously, Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. Mr. Kay received his B.A. from Cornell University’s College of Arts & Sciences and his J.D. from New York University Law School. Given his years of service with the Company and his prior experience, we believe that Mr. Kay has an excellent understanding of our business and the global markets in which we operate and those in which we anticipate operating in the future and therefore is able to make valuable contributions to our Board of Directors.

What is the salary of Robert Kay?

As the Interim Secretary, Interim Treasurer, and Director of iBio Inc, the total compensation of Robert Kay at iBio Inc is $908,622. There are 2 executives at iBio Inc getting paid more, with Thomas Isett having the highest compensation of $1,784,020.

How old is Robert Kay?

Robert Kay is 80, he's been the Interim Secretary, Interim Treasurer, and Director of iBio Inc since 2020. There are 2 older and 13 younger executives at iBio Inc. The oldest executive at iBio Inc is Seymour Flug, 84, who is the Independent Director.

What's Robert Kay's mailing address?

Robert's mailing address filed with the SEC is C/O IBIO, INC., 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022.

Insiders trading at iBio Inc

Over the last 14 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis, and William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.

What does iBio Inc do?

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.

iBio Inc executives and stock owners

iBio Inc executives and other stock owners filed with the SEC include:

• Thomas Isett,
  Chairman of the Board, Chief Executive Officer
• Thomas F. Isett III,
  CEO, Pres & Chairman
• Robert Kay,
  Interim Secretary, Interim Treasurer, Director
• Randy Joe Maddux,
  Chief Operating Officer
• Dr. Martin B. Brenner D.V.M., Ph.D.,
  Chief Scientific Officer
• Robert Erwin,
  President
• Robert B. Kay,
  Interim Sec. & Interim Treasurer
• James Hill,
  Independent Director
• John McKey,
  Independent Director
• Seymour Flug,
  Independent Director
• Glenn Chang,
  Independent Director
• Stephen Kilmer,
  Investor Relations
• Gary Sender,
  Independent Director
• Alexandra Kropotova,
  Independent Director
• Linda Armstrong,
  Independent Director
• John Delta,
  Principal Financial Officer, Principal Accounting Officer
• Carlos Picosse,
  Chief Exec. Officer of IBio Brazil
• Dr. Melissa Berquist Ph.D.,
  VP and Head of Vaccines & Animal Health
• Lisa Middlebrook,
  Chief HR Officer
• Robert Matthew Lutz,
  Chief Financial & Bus. Officer
• Mark A Giannone,
  Chief Financial Officer
• Kenneth Bryan Dart,
  10% owner
• Carl Desantis,
  10% owner
• Philip K. Russell,
  Director
• Arthur Y Elliott,
  Director
• Capital Ltd Portfolio Servi...,
  
• Ryan E Terence,
  Chief Scientific Officer
• Randy Joe Maddux,
  Chief Operating Officer
• Robert Matthew Lutz,
  See Remarks
• James P. Mullaney,
  Chief Financial Officer
• Evert B. Schimmelpennink,
  Director
• E Gerald Kay,
  10% owner
• Jules A. Musing,
  Director
• William D Clark,
  Director
• Martin Brenner,
  See Remarks
• Felipe Duran,
  Chief Financial Officer